香港股市 已收市

百心安-B (2185.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
67.900-2.400 (-3.41%)
收市價: 04:08PM HKT

百心安-B

Building 4
Room 302, 3rd Floor No.590 Ruiqing Road E. Zhangjiang Hi-Tech Park, Pudong New A
Shanghai 201201
China
86 21 6879 8511
https://www.bio-heart.com

版塊Healthcare
行業Biotechnology
全職員工49

高階主管

名稱標題支付行使價出生年份
Mr. Li WangExec. Chairman, CEO & GM110.45k1968
Mr. Yunqing WangCFO, Joint Company Sec. & Exec. Director198.28k1985
Dr. Bradley Stewart Hubbard D.V.M., DVMChief Medical Officer1959
Ms. Siu Ying KwokJoint Company Sec.1985
Ms. Peili WangSupervisor & Financial Mang.1984
Mr. Tao CaiSupervisor & Head of Technology of BRS1987
Mr. Chenzhao ZhangSupervisor & Head of Technology of RDN1984
截止 2021年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. Its BRS products include Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Bio-Leap, a below-the-knee BRS system used in percutaneous transluminal angioplasty for the treatment of lower extremity peripheral artery disease; and Bioheart Ultra, a BRS system for the treatment of coronary artery disease. The company's RDN products comprise Iberis 2nd, a multi-electrode RDN product candidate. It is also advancing the development of its balloon catheter product candidates, including balloon dilatation catheters and non-compliant balloon dilatation catheters, as well as impulse balloon dilatation catheters for the treatment of coronary artery calcification, peripheral vascular calcification, and aortic valve calcification. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

公司管治

截至 無 止,百心安-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。